MedPath

ImmunityBio

ImmunityBio logo
🇺🇸United States
Ownership
Public, Subsidiary
Established
2014-01-01
Employees
628
Market Cap
$2.9B
Website
http://www.immunitybio.com
Introduction

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

Clinical Trials
Related News

COVID-19 Supplemental Vaccine Boost to Enhance T Cell Protection in Those Who Have Already Received EUA S-Based Vaccines

Phase 1
Withdrawn
Conditions
Covid19
Interventions
First Posted Date
2021-04-13
Last Posted Date
2025-02-21
Lead Sponsor
ImmunityBio, Inc.
Registration Number
NCT04843722

COVID-19 Oral and Subcutaneous Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenovirus Platform in Healthy Volunteers in USA

Phase 1
Terminated
Conditions
Covid19
Interventions
Biological: hAd5-S-Fusion+N-ETSD (Suspension for injection)
Drug: hAd5-SFusion+ N-ETSD (Oral capsule)
First Posted Date
2021-02-01
Last Posted Date
2024-10-14
Lead Sponsor
ImmunityBio, Inc.
Target Recruit Count
28
Registration Number
NCT04732468
Locations
🇺🇸

Chan Soon - Shiong Institute for Medicine, El Segundo, California, United States

🇺🇸

Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States

COVID-19 Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenoviral Platform in Healthy South African Adults

Phase 1
Completed
Conditions
Covid19
Interventions
First Posted Date
2021-01-14
Last Posted Date
2024-11-15
Lead Sponsor
ImmunityBio, Inc.
Target Recruit Count
41
Registration Number
NCT04710303
Locations
🇿🇦

Khayelitsha Clinical Research Site, Khayelitsha, South Africa

COVID-19 Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenoviral-COVID-19 in Normal Healthy Volunteers

Phase 1
Completed
Conditions
COVID-19
Interventions
Biological: hAd5-S-Fusion+N-ETSD vaccine
First Posted Date
2020-10-19
Last Posted Date
2023-02-28
Lead Sponsor
ImmunityBio, Inc.
Target Recruit Count
34
Registration Number
NCT04591717
Locations
🇺🇸

Chan Soon - Shiong Institute for Medicine, El Segundo, California, United States

🇺🇸

Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States

Study of the Safety of Therapeutic Tx With Immunomodulatory MSC in Adults With COVID-19 Infection Requiring Mechanical Ventilation

Phase 1
Conditions
COVID
Interventions
Biological: Placebo
First Posted Date
2020-05-21
Last Posted Date
2022-02-01
Lead Sponsor
ImmunityBio, Inc.
Target Recruit Count
45
Registration Number
NCT04397796
Locations
🇺🇸

St. Francis Medical Center, Lynwood, California, United States

Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer

First Posted Date
2020-05-15
Last Posted Date
2025-05-16
Lead Sponsor
ImmunityBio, Inc.
Target Recruit Count
328
Registration Number
NCT04390399
Locations
🇺🇸

Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States

🇺🇸

Hoag memorial Presbyterian Hospital, Newport Beach, California, United States

🇺🇸

Astera Cancer Care, East Brunswick, New Jersey, United States

and more 1 locations

Study of the Safety of Therapeutic Treatment With an Immunomodulatory Agent (N-803) in Adults With COVID-19

Phase 1
Conditions
COVID-19
Interventions
Other: Saline
First Posted Date
2020-05-13
Last Posted Date
2021-08-24
Lead Sponsor
ImmunityBio, Inc.
Target Recruit Count
1
Registration Number
NCT04385849
Locations
🇺🇸

St. Francis, Lynwood, California, United States

QUILT-3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma

Phase 1
Withdrawn
Conditions
Diffuse Large B Cell Lymphoma
Large-cell Lymphoma
Lymphoma, B-Cell
Lymphoma
Interventions
First Posted Date
2019-08-09
Last Posted Date
2025-02-21
Lead Sponsor
ImmunityBio, Inc.
Registration Number
NCT04052061
Locations
🇺🇸

Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States

QUILT-3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers

Phase 1
Active, not recruiting
Conditions
Locally Advanced Solid Tumor
Metastatic Cancer
Solid Tumor
Interventions
Biological: PD-L1 t-haNK
First Posted Date
2019-08-08
Last Posted Date
2024-08-19
Lead Sponsor
ImmunityBio, Inc.
Target Recruit Count
16
Registration Number
NCT04050709
Locations
🇺🇸

Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States

QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell Carcinoma That Has Progressed After Checkpoint Therapy

Phase 2
Terminated
Conditions
Merkel Cell Carcinoma
Interventions
Biological: Avelumab
Biological: N-803
Biological: haNK™
First Posted Date
2019-02-25
Last Posted Date
2024-08-09
Lead Sponsor
ImmunityBio, Inc.
Target Recruit Count
9
Registration Number
NCT03853317
Locations
🇺🇸

University of California San Francisco, San Francisco, California, United States

🇺🇸

University of Miami, Sylvester Comprehensive Cancer Center, Miami, Florida, United States

🇺🇸

Miami Cancer Institute - Baptist Health, Miami, Florida, United States

and more 2 locations
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy